Reversible parkinsonism in a child after bone marrow transplantation and lipid-based amphotericin B therapy

Pediatric Infectious Disease Journal

Volumn 17, Issue 5, 1998, Pages 433-434

  Manley, Thomas J ^a   Chusid, Michael J ^a   Rand, Scott D ^a   Wells, Donald ^b   Margolis, David A ^a,c  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b A Program of the Seton Brain   (United States)

^c Midwest Athletes Against Childhood Cancer Inc   (United States)

Author keywords

Bone marrow transplantation; Leukoencephalopathy; Lipid based amphotericin B; Neurotoxicity; Parkinsonism

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CYCLOPHOSPHAMIDE; CYTARABINE;

ALTERNARIA; ANTIMICROBIAL THERAPY; APLASTIC ANEMIA; ARTICLE; BLOOD BRAIN BARRIER; BONE MARROW TRANSPLANTATION; CASE REPORT; CHILD; DELTA RHYTHM; FRONTAL CORTEX; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSONISM; PRIORITY JOURNAL; SINUSITIS; WHOLE BODY RADIATION;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; BONE MARROW TRANSPLANTATION; BRAIN; CHILD; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PARKINSON DISEASE; TRANSPLANTATION CONDITIONING;

EID: 0031779124     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199805000-00021     Document Type: Article

References (18)

1. Schaffner CP. Polyene macrolides in clinical practice: pharmacology and adverse and other effects. In: Omura S, ed. Macrolide antibiotics: chemistry, biology, and practice. New York: Academic Press, 1984:457-507.
2. Walker RW, Rosenblum, MK. Amphotericin B-associated leukoencephalopathy. Neurology 1992;42:2005-10.
3. Devinsky O., Lemann W, Evans A, et al. Akinetic mutism in a bone marrow transplant recipient following total-body irradiation and amphotericin B chemoprophylaxis. Arch Neurol 1987;44:414-17.
4. Ellis WG, Sobel RA, Nielson SL. Leukoencephalopathy in patients treated with amphotericin B methyl ester. J Infect Dis 1982;146:125-37.
5. Mott SH, Packer RJ, Vezina LG, et al. Encephalopathy with parkinsonian features in children following bone marrow transplantation and high-dose amphotericin B. Ann Neurol 1995;37:810-14.
6. Balmaceda CM, Walker RW, Castro-Malaspina H, Dalmau J. Reversal of amphotericin-B-related encephalopathy. Neurology 1994;44:1183-4.
7. Corsins JP. Clinical MR Spectroscopy: fundamentals, current applications, and future potential. Am J Roentgenol 1995; 164:1337-47.
8. Tzika AA, Vigneron DB, Ball WS, Dunn RS, Kirks DR. Localized proton MR spectroscopy of the brain in children. J Magn Reson Imaging 1993;3:719-29.
9. Packer RJ, Meadows AT, Rorke LB, Goldwein JL, D'Angio G. Long-term sequelae of cancer treatment on the central nervous system in childhood. Med Pediatr Oncol 1987;15:241-53.
10. Wiznitzer M, Packer RJ, August CS, Burkey ED. Neurologic complications of bone marrow transplantation in childhood. Ann Neurol 1984;16:569-76.
11. Packer RJ, Zimmerman RA, Bilaniuk LT. Magnetic resonance (MRI) in the evaluation of treatment related central nervous system (CNS) damage. Cancer 1986;58:635-40.
12. Lawrence RM, Hoeprich PD, Jagdis FA, Monji N, Huston AC, Schaffner CP. Distribution of doubly radiolabeled amphotericin B methyl ester and amphotericin B in the non-human primate Macaca mulatta. J Antimicrob Chemother 1980;6: 241-9.
13. Cohen BH, Packer RJ. Adverse neurologic effects of chemotherapy and radiation therapy. In: Berg BO, ed. Neurologic aspects of pediatrics. Stoneham, MA: Butterworth-Heinemann 1992:567-94.
14. Pranzatelli MR, Mott SH, Pavlakis SG, Conry JA, Tate ED. Clinical spectrum of secondary parkinsonism in childhood: a reversible disorder. Pediatr Neurol 1994;10:131-41.
15. Delattre JY, Shapiro WR, Posner JB. Acute effects of low-dose cranial irradiation on regional capillary permeability in experimental brain tumors. J Neurol Sci 1989;90:147-53.
16. Lazarus HM, Herzig RH, Herzig GP, Phillips GL, Roessman U, Fishman DJ. Central nervous system toxicity of high-dose systemic cytosine arabinoside. Cancer 1981;48:2577-82.
17. Watson PR, Brubaker LH, Yaghmai F. Severe central nervous system toxicity from high-dose cytarabine: expressive aphasia occurring after the second day of treatment. Cancer Treat Rep 1985;69:313-4.
18. Winkleman MD, Hines JD. Cerebellar degeneration caused by high-dose cytosine-arabinoside: a clinicopathological study. Ann Neurol 1983;14:520-7.